Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Total revenues	$ 193,387	$ 234,763	$ 1,046,882	$ 619,543
Operating expenses:
Research and development	1,694,619	2,386,707	7,838,797	9,087,264
General and administrative	2,080,796	2,268,656	6,543,573	8,058,235
Total operating expenses	3,775,415	4,655,363	14,382,370	17,145,499
Loss from operations	(3,582,028)	(4,420,600)	(13,335,488)	(16,525,956)
Other income (expense):
Interest income, net	37,095	88,810	136,663	160,009
Change in fair value of note receivable		(77,454)	(560,473)	(114,870)
Total other income (expense), net	37,095	11,356	(423,810)	45,139
Net loss	$ (3,544,933)	$ (4,409,244)	$ (13,759,298)	$ (16,480,817)
Net loss per share, basic (in Dollars per share)	$ (0.81)	$ (2.32)	$ (3.95)	$ (10.3)
Net loss per share, diluted (in Dollars per share)	$ (0.81)	$ (2.32)	$ (3.95)	$ (10.3)
Weighted average common shares outstanding, basic (in Shares)	4,372,458	1,897,668	3,479,148	1,599,353
Weighted average common shares outstanding, diluted (in Shares)	4,372,458	1,897,668	3,479,148	1,599,353
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Net loss	$ (3,544,933)	$ (4,409,244)	$ (13,759,298)	$ (16,480,817)
Other comprehensive loss:
Foreign currency translation adjustments	18,116	(38,182)	(18,455)	(64,417)
Comprehensive loss	(3,526,817)	(4,447,426)	(13,777,753)	(16,545,234)
Feasibility
Revenues:
Total revenues	106,047	189,449	503,246	574,229
Grant
Revenues:
Total revenues	$ 87,340	$ 45,314	$ 543,636	$ 45,314